Bionano Genomics, Inc. (BNGO)

Bionano Genomics' stock price has experienced a significant decline over the past year. Key events impacting the stock include a strategic shift, Q3 2025 financial results, analyst ratings, Q4 and full-year 2025 financial results, increased OGM studies at conferences, and a new minor risk related to share price stability.

Bionano Genomics' business model has been transitioning towards generating recurring, high-margin revenue from consumables and software, alongside its system sales and diagnostic services. The company's focus on increasing utilization by routine users and building support for reimbursement and guideline inclusion suggests a strategy aimed at more consistent demand rather than strong seasonality. The company reported a healthy backlog of consumables demand entering 2026, indicating a steady demand for its consumables.

Bionano Genomics, Inc. is a life sciences instrumentation and genomics company focused on developing and marketing genome analysis solutions, operating within the Healthcare sector, specifically in the Medical Devices & Instruments industry, and is also categorized under Testing and Genome Analysis. The company's core business revolves around its proprietary Optical Genome Mapping (OGM) technology, including platforms for structural variation detection, OGM systems and consumables, ionic purification systems and consumables, genome analysis software, DLS reagents, and OGM-based diagnostic services.

Bionano Genomics operates globally, with a geographic footprint spanning the Americas, EMEA (Europe, the Middle East, and Africa), and Asia Pacific. The EMEA region currently generates the majority of the company's revenue.

Bionano Genomics has seen positive developments in its brand reputation over the past year, primarily driven by increased scientific validation and clinical adoption of its OGM technology. The company has experienced a rise in scientific support and clinical research publications. The Bionano Symposium 2026 showcased remarkable engagement within the global OGM community. A 47% increase in the 2026 Clinical Lab Fee Schedule for OGM usage in blood cancers is expected to strengthen Bionano's market position and accelerate adoption. Wall Street analysts generally rate BNGO as "Very Bullish" or "Hold."

The ownership structure of Bionano Genomics is a mix of institutional, retail, and individual investors. Institutional investors hold between approximately 2.23% and 11.35% of the company's stock. Public companies and individual investors hold a significant portion, ranging from approximately 70.35% to 95.09% of the stock. Insiders hold between 0.90% and 1.89% of the stock, with Thomas E. Claugus owning the most shares.